BRCA2 and ovarian cancer: Using our validated workflow, we have identified 18 deleterious mutations in 101 patients (17,8%) which is in accordance with the prevalence of BRCA1 and BRCA2 mutations reported in the Spanish hereditary breast and ovarian cancer population.